ArticlebioRxiv : the preprint server for biology2025
Unraveling the Molecular Mechanisms of ABHD5 Membrane Targeting.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
ABHD5 plays a critical role in lipid metabolism, regulating fatty acid mobilization, skin barrier formation, and phospholipid remodeling. ABHD5 lacks catalytic activity and instead functions as an essential co-regulator of PNPLA enzymes. Understanding how ABHD5 interacts with lipid droplet (LD) and endoplasmic reticulum (ER) membranes is crucial for unraveling its regulatory role in lipid metabolism and identifying potential therapeutic targets for metabolic diseases. While previous studies have modeled ABHD5 structure in solution, its function relies on membrane interactions, requiring a detailed investigation of its binding mechanisms. In this study, we employed multiscale simulations with experimental validation to reveal how ABHD5 interacts with ER and LD. Our findings show that ABHD5 binds membranes through its N-terminus and insertion segment, which subsequently triggers structural changes in the pseudosubstrate pocket and alters lipid distribution. This study also identifies key residues essential for membrane binding, providing potential targets for developing lipid metabolism modulators. These results uncover a previously unrecognized mechanism by which ABHD5 interacts with membranes, offering new insights into lipolysis regulation and potential therapeutic strategies for metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.